Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data ...
Apr 3, 2017
0
1
Computed Tomography (CT) scans are a reliable tool to establish a diagnosis of immune-related colitis, a potentially life-threatening adverse event in patients with advanced melanoma who receive the immune checkpoint inhibitor ...
Apr 3, 2017
0
2
Massachusetts General Hospital investigators have found new evidence that the tumor necrosis factor receptor type II (TNFR2) may be a major target for immuno-oncology treatments, which induce a patient's immune system to ...
Jan 17, 2017
0
22
Previous studies identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, but new research led by University of California San Diego School of Medicine scientists reveals a surprising role for these enzymes in ...
Dec 1, 2016
0
1
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 ...
Oct 8, 2016
0
5
A combination of the immunotherapies AM0010 and the immune checkpoint inhibitor pembrolizumab was well tolerated and resulted in durable objective tumor responses in some patients with renal cell carcinoma (RCC) and non-small ...
Sep 27, 2016
0
3
UT Southwestern Medical Center researchers today report on a strategy to make a major advance in cancer treatment even better, and a means to test and refine this new type of immunotherapy.
Mar 14, 2016
0
0
Radiofrequency ablation (RFA), a procedure to treat liver metastases in patients with colorectal cancer, was found to induce antitumor immune responses in human samples of primary colon tumor, and mice treated with a combination ...
Mar 1, 2016
0
31
Based on the results of EORTC trial 18071, the FDA expanded the approval of Yervoy (ipilimumab) in melanoma to include adjuvant treatment of patients with stage 3 melanoma at high risk of recurrence following complete resection.
Nov 13, 2015
0
4
For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.
Sep 25, 2015
0
51
